ESMO 2025: HER2-Targeted Therapy Advances in BTC
/ Teresa Macarulla
ESMO 2025: Nye data styrker potensialet for CDK4/6-hemmere ved tidlig brystkreft – Intervju med overlege Egil Støre Blix
/ Egil Støre Blix / Jan Andreasen
Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study
/ Igle Jan de Jong / Jan Andreasen











